Nov 20, 2024 9:00 am EST Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
Nov 13, 2024 4:01 pm EST Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Nov 12, 2024 9:00 am EST Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting
Nov 05, 2024 9:00 am EST Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13
Oct 18, 2024 4:01 pm EDT Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Oct 17, 2024 6:00 am EDT Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock
Oct 11, 2024 9:15 am EDT Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress
Oct 09, 2024 9:15 am EDT Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Oct 04, 2024 9:15 am EDT Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress